Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation

TOP - August 2017, Vol 10, No 3 - Conference Correspondent, HOPA 2017 Highlights
Chase Doyle

Anaheim, CA—Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.

At the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, Sarah Perreault, PharmD, BCPS, BCOP, Clinical Pharmacy Specialist, Bone Marrow Transplantation, Yale New Haven Hospital, CT, highlighted the need for identification of high-risk patients, and for strategies for relapse prevention.

“Prevention is the most feasible and effective means of managing relapse, and is ultimately the best way to protect the patient. There are many strategies for prevention of disease relapse, but maintenance chemotherapy is an essential part of the process,” said Dr Perreault.

Multiple Myeloma

As Dr Perreault reported, eligibility for maintenance therapy in multiple myeloma is not well-defined.

“The consensus is that any person with any stage of disease is eligible for maintenance regardless of chromosomal abnormalities. Maintenance is not going to overcome your prognostic score if you have a bad cytogenetic profile, but it does help with progression-free survival, so we recommend that all patients receive some kind of maintenance after transplant with multiple myeloma,” said Dr Perreault.

In randomized controlled trials, low-dose lenalidomide doubled progression-free survival compared with placebo. Although lenalidomide did not affect overall survival, it did give patients longer disease control, said Dr Perreault, who noted that patients are typically started with lenalidomide within the first 90 to 180 days of hematopoietic stem-cell transplantation, and that duration of therapy can extend beyond 2 years.

Where cost is an issue, bortezomib may be an option for maintenance therapy, offering approximately the same progression-free survival as lenalidomide, and fewer adverse events and second primary malignancies, she said.

In the future, pomalidomide may provide an additional option in the maintenance setting, and ixazomib, an oral proteasome inhibitor described as a “potential game-changer,” is coming down the pipeline, as well.

Hodgkin’s Lymphoma

Relapsed or primary refractory Hodg­kin’s lymphoma can be cured in 50% of patients after autologous hematopoietic stem-cell transplantation, Dr Perreault reported, but there are risk factors associated with poor prognosis, including primary refractory disease, an initial remission duration of <1 year, or the presence of extranodal or advanced-stage disease at the time of relapse. According to National Comprehensive Cancer Network guidelines, lack of chemosensitivity to pretransplant salvage or residual disease at the time of transplant are also associated with poor prognosis.

Brentuximab is currently used for maintenance therapy, based on the results of a randomized clinical trial that demonstrated significant improvement in progression-free survival compared with placebo (61% vs 43%, respectively, at 3 years).

“You’re not going to see it with these data, but there probably is an overall survival benefit, as well,” said Dr Perreault, who noted that an increased number of risk factors was associated with greater benefit in terms of progression-free and overall survival.

The optimal duration of brentuximab therapy is 1 year, but discontinuation because of adverse effects is common. Peripheral neuropathy occurred in 88% of patients.

Leukemia

Patients with acute myeloid leukemia who harbor an FLT3 mutation have high relapse rates, and may require the use of maintenance therapy. Sorafenib, a tyrosine kinase inhibitor, has shown benefits, said Dr Perreault, but only phase 1 data are currently available.

For patients with Philadelphia chromosome–positive leukemia, imatinib, another tyrosine kinase inhibitor, has been shown to improve overall survival in patients with chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. The presence of minimal residual disease after transplant is predictive of relapse, Dr Perreault reported.

Related Items
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Best Practices
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Pancreatic Cancer
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Immunotherapy
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: August 2, 2017